· By Sanofi Admin

To Approval and Beyond: Biologics vs. Traditional Prescription Drugs

Biologics Infographic

This post was authored by Cary Yonce, Vice President, General Therapeutics and Life-Cycle Management at Sanofi US.
In the second edition of the National Press Foundation’s (NPF) educational webinar series, NPF President Sandy K. Johnson discussed the path to Food and Drug Administration (FDA) approval and beyond for conventional small molecule drugs, biologics and their respective […]

VIEW FULL POST
 · By Sanofi Admin

Biologics 101: How Biotech-Driven Drug Development is Reshaping Medicine

This post was authored by Cary Yonce, Vice President, General Therapeutics and Life-Cycle Management at Sanofi US.
Last week, the National Press Foundation (NPF) held the first of three educational webinars about biologics and biosimilars sponsored by Sanofi US. NPF President Sandy K. Johnson interviewed Ed Silverman, Pharmalot writer for The Boston Globe’s Stat and Dr. […]

VIEW FULL POST
 · By Sanofi Admin

Drug Development 101: PDUFA

PDUFA

This post was authored by Barry Sickels, Vice President, Regulatory Affairs at Sanofi US
Earlier this month, we shared an overview of Advisory Committee Meetings, as part of our new Drug Development 101 series. Today, we’re sharing the mechanics of another important element of the drug development and approval process, the Prescription Drug User Fee Act […]

VIEW FULL POST
 · By Sanofi Admin

Drug Development 101: Advisory Committee Meetings

Source: FDA.gov

This post was authored by Barry Sickels, Vice President, Regulatory Affairs at Sanofi US
Do you know what happens after a promising new compound is discovered in a lab? The journey from compound to patient is a long one – in fact, it takes an average of about 10-15 years. It’s also a process that many […]

VIEW FULL POST